Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking

Gregory L. Powell, Jonna M. Leyrer-Jackson, Julianna Goenaga, Mark D. Namba, Jose Piña, Sade Spencer, Neringa Stankeviciute, Danielle Schwartz, Nicholas P. Allen, Armani P. Del Franco, Erin A. McClure, Michael Olive, Cassandra Gipson-Reichardt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

N-acetylcysteine (NAC), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug-induced changes in glutamatergic neurophysiology. In rats, nicotine-seeking behavior is associated with alterations in glutamatergic plasticity within the nucleus accumbens core (NAcore). Specifically, cue-induced nicotine-seeking is associated with rapid, transient synaptic plasticity (t-SP) in glutamatergic synapses on NAcore medium spiny neurons. The goal of the present study was to determine if NAC reduces nicotine-seeking behavior and reverses reinstatement-associated NAcore glutamatergic alterations. Rats were extinguished from nicotine self-administration, followed by subchronic NAC administration (0 or 100 mg/kg/d) for 4 days prior to cue-induced reinstatement. NAcore synaptic potentiation was measured via dendritic spine morphology and mRNA and protein of relevant glutamatergic genes were quantified. Nicotine-seeking behavior was not reduced by subchronic NAC treatment. Also, NAcore transcript and protein expression of multiple glutamatergic genes, as well as spine morphological measures, were unaffected by subchronic NAC. Finally, chronic NAC treatment (15 days total) during extinction and prior to reinstatement significantly decreased extinction responding and reduced reinstatement of nicotine-seeking compared to vehicle. Together, these results suggest that chronic NAC treatment is necessary for its therapeutic efficacy as a treatment strategy for nicotine addiction and relapse.

Original languageEnglish (US)
Article numbere13958
JournalPhysiological Reports
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acetylcysteine
Nicotine
Cues
Nucleus Accumbens
Therapeutics
Excitatory Amino Acid Agents
Dendritic Spines
Neurophysiology
Neuronal Plasticity
Self Administration
Psychological Extinction
Synapses
Genes
Proteins
Spine
Neurons
Recurrence
Messenger RNA
Pharmaceutical Preparations

Keywords

  • N-acetylcysteine
  • Nicotine
  • Relapse
  • Synaptic Plasticity

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking. / Powell, Gregory L.; Leyrer-Jackson, Jonna M.; Goenaga, Julianna; Namba, Mark D.; Piña, Jose; Spencer, Sade; Stankeviciute, Neringa; Schwartz, Danielle; Allen, Nicholas P.; Del Franco, Armani P.; McClure, Erin A.; Olive, Michael; Gipson-Reichardt, Cassandra.

In: Physiological Reports, Vol. 7, No. 1, e13958, 01.01.2019.

Research output: Contribution to journalArticle

Powell, GL, Leyrer-Jackson, JM, Goenaga, J, Namba, MD, Piña, J, Spencer, S, Stankeviciute, N, Schwartz, D, Allen, NP, Del Franco, AP, McClure, EA, Olive, M & Gipson-Reichardt, C 2019, 'Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking', Physiological Reports, vol. 7, no. 1, e13958. https://doi.org/10.14814/phy2.13958
Powell, Gregory L. ; Leyrer-Jackson, Jonna M. ; Goenaga, Julianna ; Namba, Mark D. ; Piña, Jose ; Spencer, Sade ; Stankeviciute, Neringa ; Schwartz, Danielle ; Allen, Nicholas P. ; Del Franco, Armani P. ; McClure, Erin A. ; Olive, Michael ; Gipson-Reichardt, Cassandra. / Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking. In: Physiological Reports. 2019 ; Vol. 7, No. 1.
@article{473931814a5842018db4b76f88561862,
title = "Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking",
abstract = "N-acetylcysteine (NAC), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug-induced changes in glutamatergic neurophysiology. In rats, nicotine-seeking behavior is associated with alterations in glutamatergic plasticity within the nucleus accumbens core (NAcore). Specifically, cue-induced nicotine-seeking is associated with rapid, transient synaptic plasticity (t-SP) in glutamatergic synapses on NAcore medium spiny neurons. The goal of the present study was to determine if NAC reduces nicotine-seeking behavior and reverses reinstatement-associated NAcore glutamatergic alterations. Rats were extinguished from nicotine self-administration, followed by subchronic NAC administration (0 or 100 mg/kg/d) for 4 days prior to cue-induced reinstatement. NAcore synaptic potentiation was measured via dendritic spine morphology and mRNA and protein of relevant glutamatergic genes were quantified. Nicotine-seeking behavior was not reduced by subchronic NAC treatment. Also, NAcore transcript and protein expression of multiple glutamatergic genes, as well as spine morphological measures, were unaffected by subchronic NAC. Finally, chronic NAC treatment (15 days total) during extinction and prior to reinstatement significantly decreased extinction responding and reduced reinstatement of nicotine-seeking compared to vehicle. Together, these results suggest that chronic NAC treatment is necessary for its therapeutic efficacy as a treatment strategy for nicotine addiction and relapse.",
keywords = "N-acetylcysteine, Nicotine, Relapse, Synaptic Plasticity",
author = "Powell, {Gregory L.} and Leyrer-Jackson, {Jonna M.} and Julianna Goenaga and Namba, {Mark D.} and Jose Pi{\~n}a and Sade Spencer and Neringa Stankeviciute and Danielle Schwartz and Allen, {Nicholas P.} and {Del Franco}, {Armani P.} and McClure, {Erin A.} and Michael Olive and Cassandra Gipson-Reichardt",
year = "2019",
month = "1",
day = "1",
doi = "10.14814/phy2.13958",
language = "English (US)",
volume = "7",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic treatment with N-acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking

AU - Powell, Gregory L.

AU - Leyrer-Jackson, Jonna M.

AU - Goenaga, Julianna

AU - Namba, Mark D.

AU - Piña, Jose

AU - Spencer, Sade

AU - Stankeviciute, Neringa

AU - Schwartz, Danielle

AU - Allen, Nicholas P.

AU - Del Franco, Armani P.

AU - McClure, Erin A.

AU - Olive, Michael

AU - Gipson-Reichardt, Cassandra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - N-acetylcysteine (NAC), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug-induced changes in glutamatergic neurophysiology. In rats, nicotine-seeking behavior is associated with alterations in glutamatergic plasticity within the nucleus accumbens core (NAcore). Specifically, cue-induced nicotine-seeking is associated with rapid, transient synaptic plasticity (t-SP) in glutamatergic synapses on NAcore medium spiny neurons. The goal of the present study was to determine if NAC reduces nicotine-seeking behavior and reverses reinstatement-associated NAcore glutamatergic alterations. Rats were extinguished from nicotine self-administration, followed by subchronic NAC administration (0 or 100 mg/kg/d) for 4 days prior to cue-induced reinstatement. NAcore synaptic potentiation was measured via dendritic spine morphology and mRNA and protein of relevant glutamatergic genes were quantified. Nicotine-seeking behavior was not reduced by subchronic NAC treatment. Also, NAcore transcript and protein expression of multiple glutamatergic genes, as well as spine morphological measures, were unaffected by subchronic NAC. Finally, chronic NAC treatment (15 days total) during extinction and prior to reinstatement significantly decreased extinction responding and reduced reinstatement of nicotine-seeking compared to vehicle. Together, these results suggest that chronic NAC treatment is necessary for its therapeutic efficacy as a treatment strategy for nicotine addiction and relapse.

AB - N-acetylcysteine (NAC), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug-induced changes in glutamatergic neurophysiology. In rats, nicotine-seeking behavior is associated with alterations in glutamatergic plasticity within the nucleus accumbens core (NAcore). Specifically, cue-induced nicotine-seeking is associated with rapid, transient synaptic plasticity (t-SP) in glutamatergic synapses on NAcore medium spiny neurons. The goal of the present study was to determine if NAC reduces nicotine-seeking behavior and reverses reinstatement-associated NAcore glutamatergic alterations. Rats were extinguished from nicotine self-administration, followed by subchronic NAC administration (0 or 100 mg/kg/d) for 4 days prior to cue-induced reinstatement. NAcore synaptic potentiation was measured via dendritic spine morphology and mRNA and protein of relevant glutamatergic genes were quantified. Nicotine-seeking behavior was not reduced by subchronic NAC treatment. Also, NAcore transcript and protein expression of multiple glutamatergic genes, as well as spine morphological measures, were unaffected by subchronic NAC. Finally, chronic NAC treatment (15 days total) during extinction and prior to reinstatement significantly decreased extinction responding and reduced reinstatement of nicotine-seeking compared to vehicle. Together, these results suggest that chronic NAC treatment is necessary for its therapeutic efficacy as a treatment strategy for nicotine addiction and relapse.

KW - N-acetylcysteine

KW - Nicotine

KW - Relapse

KW - Synaptic Plasticity

UR - http://www.scopus.com/inward/record.url?scp=85059829808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059829808&partnerID=8YFLogxK

U2 - 10.14814/phy2.13958

DO - 10.14814/phy2.13958

M3 - Article

VL - 7

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 1

M1 - e13958

ER -